Puma Biotechnology. Jefferies 2017 Global Healthcare Conference June Copyright 2017 Puma Biotechnology

Transcription

1 Puma Biotechnology Jefferies 2017 Global Healthcare Conference June 2017

2 Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the potential approval for a drug candidate, pre-commercial activities, the potential indications of our drug candidates and the development of our drug candidates, including, but not limited to, the anticipated timing for the commencement and completion of various clinical trials and announcement of data relative to these trials. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. All forward looking statements included in this presentation involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that we have no product revenue and no products approved for marketing; our dependence on our lead product candidate PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that results of clinical trials may not support our drug candidate claims; even if approved, the risk that physicians and patients may not accept or use our products; our reliance on third parties to conduct our clinical trials and to formulate and manufacture our drug candidates; our dependence on licensed intellectual property; and the other risk factors disclosed in our periodic reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the fiscal year ended December 31, Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law. 2

3 HER2+ Breast Cancer Extended adjuvant monotherapy Product Pipeline across the breast cancer therapy spectrum Phase I Phase II Phase III Registration Approval CONTROL ExteNET (Phase III HER2+ EBC) NDA filed 07/16 MAA filed 06/16 EAP/MAP Metastatic Monotherapy or combination therapy FB-10: T-DM1 + neratinib NSABP FB-7 NEfERTT (Phase II HER2+MBC) NALA (Phase III 3 rd Line HER2+ MBC) Metastatic w/ brain mets Monotherapy or combination therapy Neoadjuvant Combination with standard therapy HER2-mutant Breast Cancer/Solid Tumors Metastatic (± fulvestrant in MBC) SUMMIT (Basket Trial) Phase II trial (WashU) TBCRC-022 I-SPY 2 NSABP FB-7 3

4 ExteNET Trial - HER2 Positive Extended Adjuvant Breast Cancer Randomize 1:1 - HER2 positive breast cancer - Completed 1 year prior adjuvant treatment with trastuzumab prior to randomization - Lymph node negative, positive or residual invasive disease after neoadjuvant treatment 2840 patients total (1 year) Placebo (1 year) Primary endpoint: Invasive Disease Free Survival (IDFS) Secondary endpoints: Disease Free Survival Including Ductal Carcinoma in Situ (DFS-DCIS), Time to Distant Recurrence, Incidence of CNS recurrence, Overall Survival No loperamide prophylaxis used to prevent neratinib related diarrhea 4

5 Disease-free survival (%) Kaplan-Meier Estimates of Disease Free Survival ITT Population % 95.6% 93.9% 91.6% P-value = HR (95% CI) = 0.67 ( ) Placebo No. at risk Placebo Months after randomization

6 Disease-free survival (%) Kaplan-Meier Estimates of DFS Centrally Confirmed HER2 Positive Population % 94.9% 94.7% 90.6% P-value = HR (95% CI) = 0.51 ( ) Placebo Months after randomization No. at risk Placebo

7 Comparator Adjuvant Registration Studies Study Design Extended adjuvant HER2+ BC DFS DFS-DCIS Reduction in risk of disease recurrence HR p HR p DFS DFS- DCIS ExteNET Local HER % 37% 2.3% (24 mo) HERA 2 years Absolute reduction in risk of disease recurrence DFS Central HER < % 51% 4.1% (24 mo) DFS- DCIS 2.9% (24 mo) 4.5% (24 mo) Central HER ND 2.4% (24 mo) Extended adjuvant HR+ EBC post tamoxifen Rx (HER2+ and HER2-) MA.17 Letrozole (post 5yrs tamoxifen) Adjuvant treatment HR+ EBC (HER2+ and HER2-) 0.62 < % (24 mo) Arimidex 5 yrs Rx % 2.8% (5 yrs) Aromasin 2-3 yrs tamoxifen Aromasin 0.69 < % 3.4% (5 yrs) Copyright 2017 Puma Copyright Biotechnology Puma Biotechnology 7

8 Disease-free survival (%) Kaplan-Meier Estimates of DFS Hormone Receptor Positive Patients ITT Population % 96.0% 95.4% 91.2% P-value = HR (95% CI) = 0.51 ( ) Placebo Months after randomization No. at risk Placebo Copyright 2017 Puma Copyright Biotechnology Puma Biotechnology 8

9 Crosstalk between ER and HER2 Signaling Pathways: Rationale for Dual and Hormonal Therapy *Inhibition of cross talk not seen in extended adjuvant trials of Herceptin (HERA 2 year) or Tykerb (TEACH) Copyright 2017 Puma Copyright Biotechnology Puma Biotechnology Source: Prat and Baselga. Nat Clin Practice Onc 2008;5:

10 Disease-free survival 5-year Analysis Shows Durable idfs Benefit ITT Population % 95.5% 94.3% 92.2% 91.2% 90.2% 91.7% 90.2% 2.5% Δ 89.1% 87.7% HR (95% CI): 0.73 ( ) Two-sided P=0.008 Placebo 0.4 At risk (Descriptive P value) Months after randomization Placebo

11 Disease-free survival idfs by Hormone Receptor Status 5-Year Analysis Hormone receptor positive Hormone receptor negative % 96.1% 95.4% 93.6% 92.6% 91.2% 91.7% 4.4% Δ 89.8% 88.5% 86.8% 94.7% 97.5% 92.8% 91.8% 90.8% 90.4% 89.9% 88.9% 89.3% 88.8% HR (95% CI): 0.60 ( ) Two-sided P=0.002 HR (95% CI): 0.95 ( ) Two-sided P= (Descriptive P value) Placebo Months after randomization At risk Placebo Months after randomization Placebo

12 ExteNET-HER2+ Extended Adjuvant Breast Cancer Filed NDA for US FDA approval (July 2016) Filed MAA for EU approval (June 2016) Label revised to include patients treated up to one year from completion of adjuvant Herceptin (March 2017) Managed Access Program (MAP) launched Q4 16 Expanded Access Program (EAP) launched Q1 17 FDA Oncologic Drugs Advisory Committee voted to recommend approval (May 24, 2017) Anticipated PDUFA Date (July 2017) 12

13 (PB272) Safety Over 3,000 patients treated with neratinib prior to Puma licensing drug - Main Grade 3/4 AE-Diarrhea (previously ~30% Grade 3/4) Typically a first cycle effect (first 28 days) Historically treated with antidiarrheal agents (loperamide) after diarrhea occurs Treated with dose reductions after diarrhea occurs Puma introduced diarrhea prophylaxis with loperamide Given Day 1 with neratinib dose for first cycle High dose of loperamide initially (8-16mg) Taper dose during cycle 1 13

14 Loperamide Prophylaxis Reduces Duration and Incidence of -induced Diarrhea No prophylaxis Loperamide prophylaxis Target population HER2+ MBC HER2+ MBC HER2+ MBC HER2+ EBC (ExteNET) HER2+ MBC HER2+ MBC HER2 mutated NSCLC HER2 mutated NSCLC HER2 mutated tumors Protocoldirected therapy Paclitaxel + Herceptin + + Torisel Paclitaxel + Herceptin + + Torisel + Torisel Loperamide prophylaxis Total patients (N) Grade 3 diarrhea None 16 mg 6 mg during cycle (53%) 12 (32%) 20 (30%) (40%) (17%) 2 (14%) 1 (8%) 10 (12%) Noncompliant with Loperamide 0 4 (57%) of 7 1 (50%) of 2 1 (100%) Duration of TE diarrhea (days) Includes 1 grade 4 event Ustaris et al. Am J Hematol Oncol

15 CONTROL Study Design Phase 2 trial to characterize the incidence and severity of diarrhea in patients with HER2+ early breast cancer treated with neratinib and loperamide prophylaxis +/- an investigational agent 1 year of therapy HER2+ early BC Received up to 1 year of adjuvant trastuzumab Stage I 3c HR (ER/PR) +/ Loperamide prophylaxis 240 mg/day (endocrine therapy as indicated) As needed Anti-inflammatory agent or bile acid sequestrant (Cycle 1) Day 57 onwards Cycle 1-2 STUDY ENDPOINTS Primary endpoint: Incidence of grade 3 diarrhea Secondary endpoints: Frequency distribution of maximum-grade diarrhea; incidence and severity of diarrhea by loperamide exposure 15

16 Analysis Treatment Cohort Population CONTROL Study Flowchart Stage 1-3c HER2+ breast cancer Trastuzumab-based adjuvant therapy completed within 1 year Sequential investigational cohorts Loperamide cohort n~120 planned (Original protocol Amendment 1 and 2) Budesonide cohort n=40 planned (Amendment 3) Colestipol cohort n=40 planned (Amendment 4) Investigational cohort n=40 planned (Amendment 4) Loperamide prophylaxis Loperamide prophylaxis Budesonide Loperamide prophylaxis Colestipol Loperamide prophylaxis To be decided Interim analysis (N=137) Preliminary analysis (N=64) Preliminary analysis (N=26) Planned enrollment start date:

17 CONTROL vs ExteNET: Treatment-Emergent Diarrhea Characteristics Loperamide prophylaxis of treatment-emergent reduces incidence and severity diarrhea of diarrhea CONTROL 1 ExteNET 2 Loperamide prophylaxis Loperamide prophylaxis Loperamide prophylaxis Loperamide (original + modified) + budesonide + colestipol prn N (at data cut-off) Any grade Grade Grade Grade Grade Median duration of neratinib treatment, months Ibrahim et al. AACR Chan et.al. Lancet Oncol

18 CONTROL vs ExteNET: Treatment-Emergent Diarrhea Significant improvement seen with CONTROL prophylaxis Ibrahim et al. AACR

19 CONTROL vs ExteNET: Treatment-Emergent Diarrhea Loperamide prophylaxis reduces diarrhea duration Median cumulative duration per patient, days CONTROL 1 ExteNET 2 Loperamide prophylaxis (original + modified) Loperamide prophylaxis + budesonide Loperamide prophylaxis + colestipol Loperamide prn (n=127) (n=64) (n=26) (n=1408) Any grade Grade Grade 3 a Treatment duration, months Median a No grade 4 events in the CONTROL study; one grade 4 event in the ExteNET study 1. Ibrahim et.al. AACR Chan et.al. Lancet Oncol

20 CONTROL vs ExteNET: Treatment-Emergent Diarrhea Loperamide prophylaxis reduces diarrhea episodes Loperamide prophylaxis with or without the addition of budesonide reduces the number of diarrhea episodes experienced by patients Median diarrhea episodes per patient CONTROL 1 ExteNET 2 Loperamide prophylaxis (original + modified) Loperamide prophylaxis + budesonide Loperamide prophylaxis + colestipol Loperamide prn (n=137) (n=64) (n=26) (n=1408) Any grade Grade Grade 3 a a No grade 4 events in the CONTROL study; one grade 4 event in the ExteNET study. 1. Ibrahim et.al. AACR Chan et.al. Lancet Oncol

21 Loperamide Prophylaxis in CONTROL Decreases Dose Reductions and Dose Holds Actions required due to diarrhea, % Loperamide prophylaxis (original + modified) CONTROL 1 ExteNET 2 Loperamide prophylaxis + budesonide Loperamide prophylaxis + colestipol Loperamide prn (n=137) (n=64) (n=26) (n=1408) Dose reduction Dose hold Discontinued treatment Hospitalization Ibrahim et al. AACR Chan et.al. Lancet Oncol

22 CONTROL Prior pertuzumab exposure affects diarrhea incidence Prior pertuzumab may result in a higher incidence of grade 3 diarrhea that is not prevented/reduced with loperamide prophylaxis alone Adding budesonide may reduce grade 3 diarrhea Prior pertuzumab exposure Loperamide prophylaxis Yes (n=55) No (n=82) Loperamide prophylaxis + budesonide Yes (n=39) No (n=25) Grade 3 diarrhea, % Ibrahim et.al. AACR

23 Antidiarrheal Prophylaxis Reduces the Incidence and Severity of Diarrhea ExteNET and CONTROL (Updated May 2017) ExteNET n= % 5% 23% None Grade 1 32% Grade 2 Grade 3 Loperamide n=137 Loperamide + budesonide n=64 Colestipol + loperamide n=39 8% 31% 22% 20% 25% 20% 46% 23% 24% 27% 28% 26% 23

24 Commercial Launch Initiatives 2016 Q Q Q Market Research (Physician & Patient) Disease Awareness Campaigns Commercial Operations (3PL, Distribution, Specialty Pharmacy, Reimbursement Hub) Patient Advocacy Partnerships; Oncology Congress Presence Marketing : Message and Market Development EU : Physician & Payer Research Managed Access, Global Value Dossiers L A U N C H Market Access : Payer Education, AMCP Dossier, NCCN Pricing Key examples (not full list of initiatives) Field Team Sizing Sales Force Copyright Puma Biotechnology 24

25 PB272 Extended Adjuvant HER2+ Breast Cancer Market Size Approximately 36,000 patients (US) with early stage HER2+ breast cancer Approximately 34,000 patients (EU) with early stage HER2+ breast cancer Treatment duration: 12 months Estimated 2015 WW Herceptin adjuvant revenue (year 1) : $4.5-$5.0 billion would be used in year 2 after adjuvant Herceptin 25

26 Treatment Paradigm for HER2+ Metastatic Breast Cancer No Prior HER2+ Rx Prior HER2+ MBC Rx Herceptin (trastuzumab) + Perjeta (pertuzumab) +docetaxel T-DM1 (EMILIA) Tykerb (lapatinib) + Xeloda (capecitabine) Herceptin + other Chemo Rx T-DM1 +/- Perjeta (MARIANNE-trial did not achieve primary endpoint December 2014) Herceptin + Tykerb + Xeloda (capecitabine) + Torisel 26

27 Phase III Trial Third Line HER2+ MBC (NALA): Study Rationale Therapy Region / Study Response Rate (%) Median PFS (weeks) Tykerb (lapatinib) Phase II lapatinib + capecitabine USA (USPI) lapatinib + capecitabine EMILIA neratinib Phase II neratinib + capecitabine Phase II

28 1:1 RANDOMIZATION Phase III Trial Third-Line HER2+ MBC (NALA) Study Design 3rd- or later-line therapy for patients with HER2+ mbc Patients with asymptomatic CNS metastatic disease are eligible Obtained SPA from FDA and review by EMA in February 2013 HER2+ mbc Received 2 prior lines of HER2- directed therapy + Capecitabine Lapatinib + Capecitabine PD PD Follow-up (Survival) n=600 STUDY OBJECTIVES Co-Primary: PFS (central) and OS Secondary: PFS (local), ORR, DoR, CBR, time to intervention for CNS metastases, safety, health outcomes

29 PB272 Third-Line HER2+ MBC Market Size Approximately 5,000-6,000 patients (US) with third-line HER2+ metastatic breast cancer Tykerb 2013 WW sales - ~$325 M (~$86 M US, ~$239M ex US) Approved in combination with Xeloda In US, Herceptin often substituted for Tykerb in combination with Xeloda Opportunity to gain market share from both Xeloda-Tykerb patients and Xeloda-Herceptin patients 29

30 1:1 RANDOMIZATION NEfERTT Trial First-Line HER2 Positive Metastatic Breast Cancer Previously untreated HER2+ locally recurrent or mbc No evidence of primary disease refractory to trastuzumab or paclitaxel No prior therapy for locally recurrent or mbc n=479 + Paclitaxel Trastuzumab +Paclitaxel PD PD Primary endpoint: Progression free survival (PFS) Secondary endpoints: Overall response rate, clinical benefit rate, safety, time to CNS mets No loperamide prophylaxis used to prevent neratinib related diarrhea Awada et al. JAMA Oncol

31 PB272 First-Line HER2+ Metastatic Breast Cancer Trial (NEfERTT) Progression Free Survival: Paclitaxel-: 12.9 months Paclitaxel-Herceptin: 12.9 months (p=0.89) Objective Response Rate: Paclitaxel-: 74.8% Paclitaxel-Herceptin: 77.6% (p=0.52) Incidence of CNS Metastases: Paclitaxel-: 8.3% Paclitaxel-Herceptin: 17.3% (p=0.002) 31

32 Free of CNS progression (%) CNS Progression -Paclitaxel Delayed Onset of CNS Metastases Group N + paclitaxel 242 Trastuzumab + paclitaxel 237 Event Median (95% CI) Not estimable Not estimable No. at risk + paclitaxel Trastuzumab + paclitaxel Hazard ratio (95% CI) = 0.48 (0.29, 0.79) Log-rank test P-value = Time (months) paclitaxel Trastuzumab + paclitaxel Awada et al. JAMA Oncol

33 NSABP FB-10 Phase I/II Trial Kadcyla (T-DM1) plus Kadcyla (T-DM1) Current second line standard of care in second line HER2 positive metastatic breast cancer Phase III EMILIA Trial (Perjeta naïve): Objective Response Rate: 43.6% Median Progression Free Survival: 9.6 months JCO 2016: Patients previously treated with Perjeta ORR (second line): 23.1% Median duration of therapy: 4.0 months 33

34 FB-10 - Phase I/II trial of Kadcyla (T-DM1) plus HER2+ MBC Must have received prior anti-her2-based therapy with pertuzumab for mbc No prior T-DM1 or HER2 TKI allowed Dose level 1: 120 mg/d Dose level 2: 160 mg/d Dose level 3: 200 mg/d Dose level 4: 240 mg/d T-DM1 3.6 mg/kg IV d1 Q3W Primary endpoint: Phase I: Recommended dose of neratinib when given with T-DM1; Phase 2: Objective response rate (CR/PR) Secondary endpoint: Clinical benefit rate (CR/PR/SD), PFS, PK, tumor biopsy for PDX model (optional) 34

35 FB-10-Phase I/II trial of Kadcyla (T-DM1) plus 100% 80% 60% PD SD CR/PR 40% 20% 0% -20% -40% -60% -80% -100% ORR (CR/PR): 9 of 16 (56%) Abraham et.al. AACR

36 (PB272) HER2+ MBC with Brain Metastases 33% of HER2+ advanced metastatic breast cancer patients develop brain metastases Phase II trial of Tykerb (lapatinib) in MBC patients with CNS metastases (n=39) 2.6% response rate in CNS metastases (Tykerb naïve) Phase II trial of Tykerb (lapatinib) in MBC patients with CNS metastases (n=242) 6% response rate in CNS metastases (Tykerb naïve) Phase II extension trial of Tykerb (lapatinib) plus Xeloda in MBC patients with CNS metastases (n=50) 20% response rate in CNS metastases 36

37 TBCRC -022 Ongoing Studies Investigating CNS Metastases Cohort 1 (neratinib monotherapy): 7.5% ORR in CNS (ASCO 2014)-85% Tykerb refractory Cohort 3: Results anticipated Q

38 % reduction in volume of CNS lesions TBCRC-022 Cohort 3a CNS Response 100 Best Volumetric Response (n=31)* Best Volumetric CNS response (n=31 evaluable pts) CNS ORR = 49% (95% CI 32-66%) 18 responses * ASCO 2017

39 HER2 mutant* Combination HER2 mutant* Monotherapy Phase II HER2 Mutation Basket Trial (SUMMIT) Study Design Breast cancer HR ( ) Biliary tract Open-label, multinational, phase 2 study of neratinib as monotherapy or in combination in patients with tumors harboring ERBB2 mutations Endometrial Gastro-esophageal Ovarian Solid tumors (Other) Monotherapy or combination therapy in HER2-mutant bladder or HR+ breast cohort * PD Breast cancer HR (+) + fulvestrant Bladder/urinary tract + paclitaxel Primary endpoint: ORR Secondary endpoints: ORR (confirmed), CBR, PFS, safety, biomarkers Simon 2-stage design: If threshold response rate hit in first evaluable 7 patients expand cohort * Documented mutations based on local testing 3939

40 Monotherapy Efficacy in HER2-mutant Patients by Tumor Type * no target lesion measurement Hyman et.al. AACR

41 Somatic Mutations in HER2 (ERBB2) Are a New Class of Oncogenic Drivers in Breast Cancer and Other Solid Tumors Incidence: - 1.6%, newly diagnosed breast cancer 1-2.4%, heavily pre-treated MBC 2-7-9%, pre-treated ER+ MBC %, invasive lobular carcinomas 4,5 Tumor characteristics: - usually mutually exclusive to HER2 amplifications - predominantly in ER-positive disease (85-90%) - enriched in invasive lobular subtype Preclinical evidence of oncogenic activity: - constitutive activation of intracellular kinase and downstream signaling pathways 6 - increased cell proliferation and tumor growth 6 - Cross-talk occurs between ER and HER2 mutation (modified clinical trial to add fulvestrant to ER positive patients) PI3K Pathway HER2 somatic mutations P P P AKT PI3K mtor Nucleus RAS ERK RAF MEK Cell cycle control and proliferation Cell survival and decreased apoptosis Cellular migration and metastasis Angiogenesis P P MAPK Pathway 1 TCGA; 2 Ma et al, ASCO 2016; 3 Wagle et al, ASCO 2016; 4 Desmedt et al, JCO 2016, 5 Deniziaut et al, Oncotargets 2016; 6 Bose et al, Cancer Disc. 2013

42 Best Change in Tumor Burden: Monotherapy (n=25) Objective response rate: 33% Still on treatment SABCS 2016

43 Best Change in Tumor Burden: + Fulvestrant (n=17) Objective response rate: 58.3% SABCS 2016

44 Phase II HER2 mutant MBC: Investigator Sponsored Study HER2 mutant, non-her2 amplified Stage IV MBC w/ documented ERBB2 mutation 240mg daily PD STUDY OBJECTIVES: 1 o endpoint: Clinical Benefit Rate (CR + PR + SD 6 months) 2 o endpoints: Correlate HER2 mutations with histology, Grade, Stage, PFS 44

45 Phase II HER2 mutant MBC: Investigator Sponsored Study Interim data presented at 2016 ASCO Annual Meeting monotherapy (n=14) Clinical benefit rate: 36% (1 CR, 1 PR, 3 stable disease> 6 months) PFS: 5.0 months 94% of patients were HR positive Preclinical data shows cross talk between HER2 mutation and ER Protocol amended to treat with combination of neratinib plus fulvestrant Additional data anticipated

46 Puma-Expected Milestones Report additional data from Phase II CONTROL trial (loperamide + budesonide prophylaxis (Q2 17) Report Interim Phase I/II data from neratinib plus Kadcyla (T-DM1) in HER2-positive metastatic breast cancer trial (Q2 17) Report Phase II data from SUMMIT basket trial of neratinib in patients with HER2 mutations (Q2 17) Report Phase II trial in MBC patients with brain metastases (Q2 17) Report final 5-year DFS data from ExteNET (Q2 17) Report Phase III trial in third-line MBC patients (Q2 17) Regulatory decision in US/EU on neratinib in extended adjuvant HER2 positive early stage breast cancer (Q3 17) 46

47 Intellectual Property Composition of matter patent issued (expires 2025) Can be extended w/ Hatch/Waxman Use in the treatment of cancer issued (expires 2025) Two polymorph patents issued (both expire 2028) Combination with capecitabine (expires 2031) Use in extended adjuvant breast cancer (expires 2030) Composition of specific salt of neratinib (recently issued) Additional use patents filed 47

48 Intellectual Property on EGFR T790M Mutations Issued claims in Europe, Asia, Australia (expires 2026) Possibility to extend up to 5 years Pending claims in United States Patent claims upheld after European Opposition Hearing (February 2014) Claims for the pharmaceutical composition comprising an irreversible EGFR inhibitor for use in treating cancer having a T790M mutation Claims for the pharmaceutical composition for use in the treatment of cancer including lung cancer and non-small cell lung cancer 48

49 Experienced Management Team Alan H. Auerbach Chairman, Chief Executive Officer, President, Founder -Chief Executive Officer, President, Founder, Cougar Biotechnology Richard Bryce, MD Senior Vice President Clinical Research and Development -Onyx, Roche, ICON Clinical Research Charles R. Eyler Senior Vice President, Finance and Treasurer -Cougar Biotechnology, Hayes Medical Steven Lo Chief Commercial Officer -Corcept Therapeutics, Genentech 49

50 Board of Directors Alan H. Auerbach Chairman, Chief Executive Officer, President, Founder Puma Biotechnology, Inc. Jay Moyes Former CFO, Myriad Genetics Adrian Senderowicz, M.D. Chief Medical Officer, Cerulean; Former Chief Medical Officer and SVP, Clinical and Regulatory, Ignyta, Inc.; Sanofi, Astrazeneca; FDA (Division of Oncology Drug Products) Troy Wilson, PhD, JD CEO, Kura Oncology; CEO, Wellspring Biosciences; CEO Avidity Nanomedicines; Former CEO, President, Intellikine Frank Zavrl Former Partner, Adage Capital Management 50

51 Puma Biotechnology-Financial Currently Trading on NASDAQ: PBYI Cash position at March 31, 2017: $194.0 million Net cash used in operating activities (burn) in Q1 2017: $36.0 million Completed $172.5 million Public Offering (October 2016) Issued 4,312,500 shares at $40.00 per share Shares issued and outstanding: 37.0 million 51

52 Company Highlights In licensing driven business model mitigates R&D risk PB272 (neratinib) - clinical stage candidate targeting multiple oncology indications HER2+ Extended Adjuvant Breast Cancer HER2+ Metastatic Breast Cancer HER2+ Metastatic Breast Cancer with Brain Metastases HER2+ Neoadjuvant Breast Cancer HER2 Mutated Non-Small Cell Lung Cancer HER2 Mutated Breast Cancer HER2 Mutated Solid Tumors Retained commercial rights to PB272 Strong Phase II and Phase III data for PB272 (single agent and in combination with chemotherapy) Potential for multiple clinical and regulatory milestones over next 6-12 months 52

53 Puma Biotechnology Jefferies 2017 Global Healthcare Conference June 2017

54 Puma Biotechnology Jefferies 2017 Global Healthcare Conference APPENDIX June 2017

55 Disease-free survival (%) DFS in patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab Intention-to-treat population % 95.2% 93.8% 90.9% Two sided P-value = HR (95% CI) = 0.63 ( ) No. at risk Placebo * p-value descriptive 50 0 / Placebo treatment Months after randomization Placebo

56 Disease-free survival (%) Interim 5-year DFS in patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab Intention-to-treat population % 93.8% 92.0% 90.8% 95.2% 89.9% 91.0% 89.5% 88.3% 86.8% Two sided P-value = HR (95% CI) = 0.72 ( ) No. at risk Placebo * p-value descriptive Months after randomization / Placebo treatment Placebo

57 Disease-free survival (%) DFS in HR+ patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab HR+ patients % 96.0% 95.3% 90.8% Two sided P-value = HR (95% CI) = 0.49 ( ) No. at risk Placebo 50 0 / Placebo treatment Months after randomization Placebo * p-value descriptive 57

58 Disease-free survival (%) Interim 5-year DFS in HR+ patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab HR+ patients % 96.1% 94.9% 91.3% 93.5% 89.3% 92.6% 87.8% 91.4% 85.9% 70 Two sided P-value = HR (95% CI) = 0.57 ( ) No. at risk Placebo * p-value descriptive Months after randomization / Placebo treatment Placebo

59 Disease-free survival (%) DFS in HR patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab HR patients % 94.1% 91.7% 91.1% Two sided P-value = HR (95% CI) = 0.83 ( ) No. at risk Placebo 50 0 / Placebo treatment Months after randomization Placebo * p-value descriptive 59

60 Disease-free survival (%) Interim 5-year DFS in HR patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab HR patients % 92.3% 89.9% 94.0% 88.9% 90.6% 87.9% 89.8% 88.2% 87.8% Two sided P-value = HR (95% CI) = 0.94 ( ) No. at risk Placebo * p-value descriptive Months after randomization / Placebo treatment Placebo

61 Disease-free survival (%) DFS in centrally confirmed HER2+ (ccher2+) patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab ccher2+ patients % 94.1% 94.5% 89.9% Two sided P-value <0.001 HR (95% CI) = 0.49 ( ) No. at risk Placebo 50 0 / Placebo treatment Months after randomization Placebo * p-value descriptive 61

62 Interim 5-year DFS in ccher2+ patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab Disease-free survival (%) ccher2+ patients % 94.1% 94.3% 90.0% 92.2% 89.0% 91.1% 87.5% 90.6% 86.7% 70 Two sided P-value = 0.01 HR (95% CI) = 0.65 ( ) No. at risk Placebo * p-value descriptive Months after randomization / Placebo treatment Placebo